Nursing home residents who received an RSV vaccine were 73% less likely to be hospitalized with the virus and 56% less likely to die from it, according to a study of nearly 600,000 Medicare beneficiaries published this week in JAMA Internal Medicine.
The finding arrives weeks before respiratory virus season, and it addresses a population that has been largely missing from the evidence base. Clinical trials of RSV vaccines enrolled community-dwelling older adults. Residents of long-term care facilities are frailer, carry more chronic conditions and take more medications, and families have had reason to ask whether trial results transfer to them.
Four Outcomes, One Large Claims Data Set
Researchers led by the Centers for Disease Control and Prevention examined Medicare claims for 597,430 people living in nursing homes. They measured the vaccine’s effect on hospitalizations, serious RSV complications, thromboembolic events, and death.
Estimated effectiveness was 73% against hospitalization, 59% against serious RSV outcomes, 66% against thromboembolic events, which are potentially dangerous blood clots, and 56% against death. The study appears in JAMA Internal Medicine, which published it alongside an independent commentary.
The authors wrote that the results add to the evidence that RSV vaccines protect a vulnerable group of older adults, and that the size of the protection lines up with what other studies have found in different older populations.
An accompanying commentary by Christopher Radcliffe, MD, of Yale University School of Medicine and Rupak Datta, MD, PhD, of the Veterans Affairs Connecticut Healthcare System described the result as robust and said it demonstrates “the preserved benefits of vaccination even among nursing home residents with extensive multimorbidity.”
The Evidence Has Real Limits Worth Naming
This is an observational study built on medical claims, not a randomized trial. That distinction matters. People who get vaccinated differ from people who do not, in ways that are not fully captured by billing records, and researchers adjust for what they can measure rather than everything that exists.
The healthy vaccinee effect is the specific concern in older populations. Residents well enough to be brought to a vaccination clinic may be healthier at baseline than residents who are not, which can inflate apparent effectiveness. Frailty and life expectancy also influence whether a clinician offers a vaccine at all, and neither is captured cleanly in billing codes. The authors note their estimates align with other studies in different older adult populations, which is reassuring but not a substitute for randomization.
The thromboembolic finding should be read carefully. A 66% reduction in blood clot events is biologically plausible, since severe respiratory infection drives inflammation and clotting risk. It is not evidence that the vaccine treats or prevents clots in general.
Nothing in this study changes existing recommendations. CDC recommends a single dose of any licensed RSV vaccine for all adults 75 and older, and for adults 50 to 74 who are at increased risk of severe RSV illness. Living in a nursing home is itself one of the qualifying risk conditions in that younger group. Adults who have already received a dose are not currently advised to get another.
Questions Families Can Reasonably Raise with a Facility
Nursing home vaccination rates vary widely between facilities and between states, and residents cannot generally arrange their own vaccination. That makes this a conversation between families and administrators rather than a personal decision.
A family member or health care proxy can ask whether the resident has received an RSV vaccine, when, and which product. They can ask what the facility’s overall resident vaccination rate is and whether staff vaccination is tracked, since staff is a documented route of introduction during outbreaks. They can ask what the facility’s plan is if a resident tests positive.
Cost is generally not the obstacle it once was. RSV vaccination is covered under Medicare Part D for eligible beneficiaries with no cost sharing, and most nursing home residents have Part D coverage. Families uncertain about a specific plan can ask the facility’s pharmacy consultant or contact the plan directly.
Residents who are severely immunocompromised, who have had a serious allergic reaction to a vaccine component, or who are acutely ill may need a different approach. That is a decision for the resident’s physician, and no one should act on a news article in place of that conversation.
The Winter Ahead for Long-Term Care
RSV is a seasonal virus that typically circulates from fall through early spring in most of the United States. CDC estimates that 110,000 to 180,000 adults 50 and older are hospitalized with RSV in a typical year, and the risk of severe illness climbs with age and with certain chronic conditions.
Nursing homes carry a disproportionate share of that burden every winter. Congregate living, shared staff, close-contact care and a resident population with heart and lung disease combine to make facilities efficient settings for transmission once the virus arrives.
For the roughly 1.2 million Americans living in nursing homes and the relatives who make or influence their medical decisions, this study offers concrete numbers to guide conversations about prevention. The protection held up in this data set, even among residents with the complex health profiles typical of long-term care.
Discover more from Skilled Care Journal
Subscribe to get the latest posts sent to your email.
